01 Industry overview
The peptide therapy industry at a glance
The global peptide therapeutics market is estimated at $164.0 billion in 2026, driven by GLP-1 medicines, metabolic-disease treatment demand, expanding manufacturing capacity, and continued regulatory development.
- $164.0B[10]
- Peptide therapeutics market, 2026
- 8.7%[10]
- Forecast CAGR, 2026–2033
- 61.9%[10]
- North America share, 2025
- 63.6%[10]
- Metabolic disorders share, 2025
- Market size
- The global peptide therapeutics market was valued at $140.9 billion in 2025 and is estimated at $164.0 billion in 2026. These figures include peptide medicines across therapeutic applications and manufacturing categories.[10]
- Forecast & CAGR
- The market is projected to reach $294.6 billion by 2033, representing an 8.7% compound annual growth rate from 2026 to 2033. A separate market estimate places 2025 revenue at $49.21 billion and forecasts $83.57 billion by 2030, illustrating the effect of differing market definitions.[10][11]
- Market share & regions
- North America held 61.9% of global peptide therapeutics revenue in 2025. In peptide contract manufacturing, North America accounted for 45.2% of revenue in 2025, reflecting strong commercial GLP-1 demand and outsourcing activity.[10]
- Segmentation
- Innovative products represented 80.1% of the peptide therapeutics market in 2025, while metabolic disorders accounted for 63.6%. Parenteral administration represented 84.0%, and recombinant-DNA technology accounted for 80.2%.[10]
- Pricing
- U.S. patient-facing prices vary substantially by product, coverage, dose, and discount program. Wegovy has a manufacturer list price of $1,349.02 per package, while Lilly lists Zepbound self-pay prices of $299 per month for 2.5 mg, $399 for 5 mg, and $449 for higher doses under its purchase offer.[12][13]
- Trends, drivers & challenges
- Growth is being supported by obesity and diabetes treatment demand, particularly GLP-1 therapies, alongside investment in peptide manufacturing and generic development. Challenges include supply capacity, complex peptide impurity and immunogenicity assessment, affordability, and safety concerns surrounding unapproved products.[9][10]
- Consumer behavior & competition
- Demand is increasingly concentrated in metabolic-disease and weight-management therapies: metabolic disorders represented 63.6% of peptide therapeutics revenue in 2025. Competition includes branded products such as Wegovy and Zepbound, emerging generic GLP-1 products, and unapproved or compounded offerings that FDA says should be used only when a patient’s needs cannot be met by an approved medicine.[10][9]
- M&A
- In July 2026, Samsung Biologics announced an all-cash offer to acquire PolyPeptide, offering a 40% premium to PolyPeptide’s unaffected share price of CHF 31.65. The transaction is intended to expand Samsung Biologics’ peptide capabilities and global manufacturing network.[14]
- Regulation
- FDA approved the first generic versions of liraglutide in 2025, alongside generic exenatide and glucagon approvals. In July 2026, FDA published 17 revised draft product-specific guidances for generic peptide products, while continuing to identify immunogenicity and impurity-characterization risks for several unapproved compounded peptides.[9]
- Latest news
- On November 9, 2026, FDA required safety-labeling changes for GLP-1 receptor agonists because of a potential increased risk of non-arteritic anterior ischemic optic neuropathy. The agency’s listed products include semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, and other GLP-1 medicines.[9]
02 Ranking
Top 10 Companies in the Peptide Therapy Industry
The leading companies in the peptide therapy industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 20, 2026 · Next review December 20, 2026
Eli Lilly and Company stands out for incretin therapy revenue concentration because Mounjaro and Zepbound generated 56% of its 2025 revenue, while Novo Nordisk focuses on branded obesity GLP-1 volume since it held 59.6% of global branded obesity GLP-1 volume in 2025.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in incretin therapies
Eli Lilly and Company
US
Ranked #1 · 9.6 · Incretin therapies
Why we picked it: It monetizes incretin therapy with a high concentration of 2025 revenue tied to Mounjaro and Zepbound.
Leader in GLP-1, insulin & peptides
Novo Nordisk
DK
Ranked #2 · 8.9 · GLP-1, insulin & peptides
Why we picked it: It holds a majority of branded obesity GLP-1 volume in 2025 while maintaining an operating margin of 41.3%.
Leader in peptide R&D & pipelines
Zealand Pharma
DK
Ranked #3 · 8.7 · Peptide R&D & pipelines
Why we picked it: It focuses on peptide medicines for metabolic and rare diseases, backed by long peptide research and pipeline depth.
Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Eli Lilly and Company Incretin therapies · US | 9.6 | 9.6 | 9.9 | 9.9 | 9.9 | |
Company snapshot · Eli Lilly and Company · Data as of November 20, 2026 Mounjaro and Zepbound generated 56% of Lilly's 2025 revenue.[15]
| |||||||
| 2 | Novo Nordisk GLP-1, insulin & peptides · DK | 8.9 | 9.9 | 8.2 | 7.8 | 9.9 | |
Company snapshot · Novo Nordisk · Data as of November 20, 2026 Novo Nordisk held 59.6% of global branded obesity GLP-1 volume in 2025.[16]
| |||||||
| 3 | Zealand Pharma Peptide R&D & pipelines · DK | 8.7 | 7.0 | 9.9 | 9.3 | 9.6 | |
Company snapshot · Zealand Pharma · Data as of November 20, 2026 Zealand Pharma has 27 years of peptide research and more than eight metabolic pipeline candidates.[17]
| |||||||
| 4 | Bachem Peptide ingredients · CH | 8.6 | 8.2 | 8.5 | 9.4 | 7.5 | |
Company snapshot · Bachem · Data as of November 20, 2026 Bachem is a specialist producer of peptide and oligonucleotide pharmaceutical ingredients.[18]
| |||||||
| 5 | Ipsen Somatostatin analog therapies · FR | 8.4 | 8.4 | 7.4 | 8.7 | 9.6 | |
Company snapshot · Ipsen · Data as of November 20, 2026 Somatuline and Decapeptyl generated €1.68 billion in 2025 sales.[19]
| |||||||
| 6 | Novartis Peptide oncology and endocrine therapies worldwide · CH | 8.4 | 7.9 | 8.3 | 8.2 | 9.6 | |
Company snapshot · Novartis · Data as of November 20, 2026 Novartis is identified among major companies in the global peptide therapeutics market.[11]
| |||||||
| 7 | AstraZeneca Peptide and metabolic medicines worldwide · GB | 8.3 | 7.9 | 7.9 | 8.3 | 9.6 | |
Company snapshot · AstraZeneca · Data as of November 20, 2026 AstraZeneca is identified among major companies in the global peptide therapeutics market.[11]
| |||||||
| 8 | AbbVie Peptide hormone and specialty therapies worldwide · US | 8.3 | 7.9 | 8.0 | 8.3 | 9.6 | |
Company snapshot · AbbVie · Data as of November 20, 2026 AbbVie is identified among major companies in the global peptide therapeutics market.[11]
| |||||||
| 9 | GSK Peptide therapeutics and specialty medicines worldwide · GB | 8.1 | 7.9 | 7.5 | 8.0 | 9.2 | |
Company snapshot · GSK · Data as of November 20, 2026 GSK is identified among major companies in the global peptide therapeutics market.[11]
| |||||||
| 10 | PolyPeptide Peptide CDMO and commercial API manufacturing · CH | 7.9 | 8.0 | 7.0 | 9.0 | 7.0 | |
Company snapshot · PolyPeptide · Data as of November 20, 2026 PolyPeptide supports 68 commercial peptide-therapy projects across its global manufacturing network.[20]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 20, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 20). Top 10 companies in the peptide therapy industry. In Peptide Therapy Industry Statistics. Gitnux. https://gitnux.org/peptide-therapy-industry-statistics/#top-companies
Revenue of the largest peptide therapy companies
Eli Lilly and Company leads with $65.2B in annual revenue (group level, converted to USD).
03 Trends & forecasts
Top 10 Peptide Therapy Industry Trends & Forecasts 2027
What is changing in the peptide therapy industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01GLP-1 demand continues accelerating
High confidenceEli Lilly reported third-quarter 2026 Mounjaro revenue of $10.723 billion, up 65% year over year, while Zepbound revenue reached $5.352 billion, up 49%. For the first nine months of 2026, Zepbound revenue increased 56% to $14.440 billion, showing that metabolic peptides remain the industry’s principal growth engine.[21]
Forecast 2027: In 2027, metabolic indications should remain the largest source of peptide-therapy growth. Competition will broaden, but obesity and diabetes products are likely to account for most incremental industry revenue.
02Oral peptide adoption expands rapidly
High confidenceNovo Nordisk reported more than three million prescriptions for Wegovy pill during its first five months in the United States, with more than 80% of new prescriptions going to people who had not previously used GLP-1 therapy. The tablet achieved average weight loss of 16.6% in its phase 3 OASIS 4 study when all patients remained on treatment.[22]
Forecast 2027: By 2027, oral formulations should take a growing share of new obesity-treatment starts, especially among patients reluctant to use injections. Injectable products will remain important because of established efficacy, dosing flexibility and manufacturing scale.
03Dual and multi-agonists intensify competition
High confidenceTirzepatide products generated $10.723 billion in Mounjaro revenue and $5.352 billion in Zepbound revenue during the third quarter of 2026. Novo Nordisk is also advancing CagriSema and next-generation amylin-based candidates, indicating that competition is moving beyond single-pathway GLP-1 medicines.[21][22]
Forecast 2027: In 2027, differentiated combinations and multi-agonists should capture increasing research and commercial attention. Clinical programs will compete primarily on weight loss, tolerability, lean-mass preservation, dosing frequency and broader cardiometabolic outcomes.
04Manufacturing capacity keeps expanding
High confidenceLilly stated in its 2026 regulatory filing that it has undertaken significant manufacturing expansion initiatives to support current and prospective incretin products, with additional capacity expected to become operational over the next several years. Lilly also announced that it had broken ground on an expansion of U.S. manufacturing for next-generation medicines.[21]
Forecast 2027: Capacity additions should reduce supply bottlenecks in 2027, particularly for high-volume GLP-1 products. The main constraint is likely to shift from aggregate capacity to qualification, fill-finish availability, device supply and regional allocation.
05Peptide CMO consolidation advances
High confidenceSamsung Biologics’ proposed all-cash acquisition of PolyPeptide, announced in July 2026, offered a 40% premium to PolyPeptide’s unaffected share price of CHF 31.65. The transaction is intended to expand Samsung Biologics’ peptide capabilities and global manufacturing network.[15]
Forecast 2027: Further acquisitions and partnerships among peptide developers, specialist manufacturers and large biologics contractors are likely in 2027. Buyers will seek integrated capabilities spanning synthesis, purification, analytical characterization and commercial-scale production.
06Generic peptide development accelerates
High confidenceFDA published 17 revised draft product-specific guidances for generic peptide products in July 2026. The guidances covered products including liraglutide, semaglutide, glucagon, calcitonin, pegcetacoplan and teriparatide, providing more specific development and bioequivalence recommendations.[9]
Forecast 2027: In 2027, the expanded guidance framework should support more abbreviated applications and greater competition for mature peptide products. Entry will remain selective because complex characterization, device comparability and manufacturing controls raise development costs.
07Realized prices face downward pressure
High confidenceLilly reported that 2026 Mounjaro and Zepbound revenue growth was partly offset by lower realized prices. Novo Nordisk also reported that its 2026 outlook reflected lower realized prices, including effects from U.S. pricing policy and loss of exclusivity in some international markets.[21][22]
Forecast 2027: Net prices are likely to decline further in 2027 as manufacturers expand self-pay offers, negotiate with payers and respond to international reference-pricing pressure. Volume growth should partly offset price erosion for leading products.
08Medicare pricing influence increases
High confidenceCMS stated that negotiations conducted in 2026 will produce negotiated prices effective in 2028, while its November 2026 final rule codified policies for later negotiation years. The agency also published the selected-drug list for the initial 2028 price-applicability year on November 2, 2026.[23]
Forecast 2027: During 2027, manufacturers will increasingly model Medicare exposure in launch pricing, contracting and indication strategy. Even before negotiated prices take effect, the policy framework should strengthen payer leverage over high-cost peptide therapies.
09Safety surveillance becomes more prominent
High confidenceOn November 9, 2026, FDA required labeling changes for all GLP-1 receptor agonists concerning a potential increased risk of non-arteritic anterior ischemic optic neuropathy. FDA cited 6.4 cases per 100,000 person-years among GLP-1 users versus 3.8 cases among placebo or non-GLP-1 comparators in an analysis of 126 randomized controlled trials.[9]
Forecast 2027: In 2027, post-market evidence generation and risk communication will become more important for GLP-1 brands. Safety signals are unlikely to eliminate demand, but they may increase monitoring requirements, prescribing caution and differentiation based on long-term outcomes.
10Unapproved peptide use faces tighter scrutiny
High confidenceFDA identified immunogenicity risks for compounded peptide products, including ipamorelin, because aggregation or peptide-related impurities may occur for certain routes of administration. FDA advisory-committee materials in 2026 also addressed BPC-157, KPV, TB-500, MOTS-c, Semax and other substances proposed for compounding use.[9]
Forecast 2027: Regulatory and quality scrutiny of unapproved and compounded peptides should intensify in 2027. Approved products with validated analytical methods, traceable supply chains and formal pharmacovigilance systems are likely to gain commercial advantage.
04 Statistics
Market Intelligence
Market intelligence shows scale across providers: 3,132 active peptide-therapy providers across eight countries on May 3, 2026, with the United States accounting for 2,731.
Firm counts and size structure in the peptide therapy industry
- 3,132 active peptide-therapy providers were listed across eight countries on May 3, 2026; the directory included clinics, telehealth platforms, compounding pharmacies and online vendors.[1]
- 12,007 of 53,215 U.S. med spas, or 23%, offered peptide therapy in the October 30, 2026 directory snapshot.[2]
- 4,770 active U.S. peptide-therapy clinics were indexed across all 50 states on March 5, 2026.[3]
- 3.8% of 12,007 U.S. med spas offering peptide therapy belonged to one of 42 matched national chains in October 2026.[2]
- 2,037 clinics and 915 503A compounding pharmacies accounted for 94.2% of 3,132 active peptide-therapy provider listings on May 3, 2026.[1]
Regional breakdown of the peptide therapy industry
- Florida had 652 and Texas 633 active peptide-therapy clinics, the two largest state totals among 4,770 U.S. clinics indexed on March 5, 2026.[3]
- Florida had 1,718 peptide-therapy med spas, the highest state count in the MedSpaStandard U.S. directory snapshot of October 2026.[2]
- The United States accounted for 2,731 of 3,132 active PeptideBase-listed providers, compared with 138 in the United Kingdom, 120 in Canada and 112 in Australia, on May 3, 2026.[1]
- Florida had the highest provider density at 7.4 peptide-therapy med spas per 100,000 residents, while Alabama had the lowest among states with at least 30 providers at 1.5 in October 2026.[2]
05 Statistics
Operating Benchmarks
Operating benchmarks quantify offering breadth and verification: 78% of 3,132 provider listings were independently verified on May 3, 2026, equal to 2,444.
Operating metrics used in the peptide therapy industry
- 78% of 3,132 active peptide-therapy provider listings were independently verified on May 3, 2026, equal to 2,444 listings.[1]
- Tirzepatide was offered by 1,745 of 4,770 indexed U.S. peptide-therapy clinics, or 36.6%, on March 5, 2026.[3]
- PeptideBase tracked 97 compounds across 3,132 active peptide-therapy provider listings on May 3, 2026.[1]
- Among 5,359 U.S. peptide-therapy providers naming their clinical team online, 49% listed a nurse practitioner and 48% listed a physician in October 2026.[2]
- Semaglutide was offered by 2,285 of 4,770 indexed U.S. peptide-therapy clinics, or 47.9%, on March 5, 2026.[3]
06 Statistics
Clients & Demand
Clients and demand data link services to reach: 68 of 3,132 active PeptideBase-listed providers accepted patients remotely across state lines on May 3, 2026.
Service penetration and outsourcing in the peptide therapy industry
- 68 of 3,132 active PeptideBase-listed providers accepted patients remotely across state lines on May 3, 2026.[1]
- 26% of 402 peptide-therapy clinics in the PeptideProbe U.S. directory offered telehealth in April 2026, equal to 103 clinics.[4]
- Peptide therapy was offered by 23% of 53,215 U.S. med spas in the October 30, 2026 MedSpaStandard directory snapshot.[2]
- 4% of 402 PeptideProbe-listed U.S. peptide-therapy clinics accepted insurance in April 2026, equal to 16 clinics.[4]
07 Statistics
Pricing
Pricing reflects recurring and entry costs for telehealth: a $349 initial consultation price and a $95 advertised follow-up or monthly check-in fee in 2026.
Fees and price levels in the peptide therapy industry
- $95 is the advertised peptide follow-up or monthly check-in fee for a U.S. telehealth provider in 2026.[5]
- $349 is the advertised initial peptide consultation price, including consultation, bloodwork and lab discussion, for a U.S. telehealth provider in 2026.[5]
- $59 per month is the advertised wellness-membership fee that includes peptide-program discounts and quarterly laboratory work at one U.S. clinic in 2026.[6]
08 Statistics
Risk & Compliance
Risk and compliance emphasizes tighter sourcing controls: 1 FDA-registered manufacturer is required as the source of peptide bulk drug substance under the HHS policy effective October 30, 2026.
Regulation and licensing in the peptide therapy industry
- 1 FDA-registered manufacturer is required as the source of peptide bulk drug substance under the HHS enforcement-discretion conditions in the United States, effective October 30, 2026.[7]
- 6 peptide bulk-drug substances are covered by HHS’s October 30, 2026 enforcement-discretion policy for specified 503A compounding conditions in the United States.[8]
- 6 named peptides remain subject to FDA’s specified compounding-safety review framework, with CJC-1295 among substances for which FDA identifies serious adverse events and limited clinical data in the United States in 2026.[9]
- 1 patient-specific prescription is required under the HHS policy for covered 503A compounded peptide products in the United States, effective October 30, 2026.[7]
Key questions about the peptide therapy industry
What is the peptide therapeutics market size in 2026?
How fast is the peptide therapeutics market expected to grow after 2026?
Which companies lead the peptide therapy industry?
What technology shifts are shaping peptide therapeutics in this period?
How is the market structured between products and metabolic disorders?
What regulatory developments are most relevant to generic and compounded peptide products in 2026?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Samuel Norberg. (2026, November 20). Peptide Therapy Industry Statistics. Gitnux. https://gitnux.org/peptide-therapy-industry-statistics
Samuel Norberg. "Peptide Therapy Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/peptide-therapy-industry-statistics.
Samuel Norberg. 2026. "Peptide Therapy Industry Statistics." Gitnux. https://gitnux.org/peptide-therapy-industry-statistics.
Sources & references
23 sources cited across this report
- peptidebase.io
medspastandard.com
- mypeptidematch.com
- peptideprobe.com
health.copergrine.com
- impacthealthclinics.com
public-inspection.federalregister.gov
govinfo.gov
fda.gov
grandviewresearch.com
thebusinessresearchcompany.com
novocare.com
zepbound.lilly.com
prnewswire.com
sec.gov
annualreport.novonordisk.com
zealandpharma.com
bachem.com
ipsen.com
report.polypeptide.com
investor.lilly.com
novonordisk.com
cms.gov